Tailored treatment for AML based on day-14 MRD test
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This phase 2 study tests whether doctors can choose the best AML treatment plan using a special blood/marrow test done on day 14. It may help people who are not good candidates for intensive chemotherapy by adjusting therapy based on early response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old and newly diagnosed with AML.
- Your doctor says you are not suitable for intensive chemotherapy.
- Your heart, lung, liver, and kidney tests fit the study limits (or you have certain medical problems that still qualify).
- Your expected survival is at least 4 weeks.
- You have not had other cancers before this study (unless allowed by the protocol).
- You do not have HIV or active hepatitis B or C, and AML has not spread to the brain/spinal cord.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three oral medications (chidamide, venetoclax, and azacitidine) for people newly diagnosed with acute myeloid leukemia (AML) who cannot receive strong chemotherapy. The goal is to see if this gentler treatment can work well with fewer side effects.
This trial studies whether selinexor combined with azacitidine and venetoclax can treat newly diagnosed acute myeloid leukemia (AML) in people who may not be able to tolerate intensive chemotherapy. It’s aimed at improving leukemia control with a treatment approach designed for patients with higher risk from other health problems.
This study looks at how well the combination of azacitidine and venetoclax works for people with newly diagnosed acute myeloid leukemia (AML) who are not healthy enough for intensive chemotherapy. The trial measures a microscopic sign of cancer called measurable residual disease (MRD) to see how the treatment affects survival.
This trial is for people with acute myeloid leukemia (AML) who are in remission but still have tiny traces of leukemia cells that can be found with sensitive tests (called MRD-positive). The study is testing a new treatment approach to try to get rid of those remaining cells and prevent the cancer from coming back.
This trial tests if adjusting chemotherapy based on early signs of leukemia can improve outcomes for people newly diagnosed with acute myeloid leukemia (AML). It might be a good fit if you are starting treatment and have a certain level of leukemia cells in your blood after a few days of therapy.
This Phase 2 trial tests a combination of venetoclax, cladribine, low-dose cytarabine, and azacitidine in people with untreated acute myeloid leukemia (AML). It may help shrink the leukemia and improve blood counts by trying a stronger, multi-drug approach.
Hear when a new MRD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.